Joseph R Osborne

List of Publications by Year
in descending order

90	3,565	172457	138484
papers	citations	29 h-index	58 g-index

95	95	95	5557
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Phase II Study of Lutetium-177â€“Labeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research, 2013, 19, 5182-5191.	7.0	370
2	Association of Black Race With Prostate Cancerâ€“Specific and Other-Cause Mortality. JAMA Oncology, 2019, 5, 975.	7.1	288
3	Racial/Ethnic Disparities in Genomic Sequencing. JAMA Oncology, 2016, 2, 1070.	7.1	250
4	A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer. Clinical Cancer Research, 2015, 21, 5277-5285.	7.0	163
5	89Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 2093-2105.	6.4	130
6	^{99m}Tc-Labeled Small-Molecule Inhibitors of Prostate-Specific Membrane Antigen: Pharmacokinetics and Biodistribution Studies in Healthy Subjects and Patients with Metastatic Prostate Cancer. Journal of Nuclear Medicine, 2014, 55, 1791-1798.	5.0	125
7	Antiâ€“prostateâ€specific membrane antigenâ€based radioimmunotherapy for prostate cancer. Cancer, 2010, 116, 1075-1083.	4.1	120
8	18F-Fluorodeoxy-glucose Positron Emission Tomography Marks MYC-Overexpressing Human Basal-Like Breast Cancers. Cancer Research, 2011, 71, 5164-5174.	0.9	113
9	Targeted Elimination of Prostate Cancer by Genetically Directed Human T Lymphocytes. Cancer Research, 2005, 65, 9080-9088.	0.9	108
10	Phase 1/2 study of fractionated dose lutetiumâ€177â€“labeled antiâ€“prostateâ€specific membrane antigen monoclonal antibody J591 (¹⁷⁷Luâ€J591) for metastatic castrationâ€resistant prostate cancer. Cancer, 2019, 125, 2561-2569.	4.1	100
11	Prostate-specific membrane antigen-based imaging. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 144-154.	1.6	96
12	Exome Sequencing of African-American Prostate Cancer Reveals Loss-of-Function ERF Mutations. Cancer Discovery, 2017, 7, 973-983.	9.4	94
13	Positron Emission Tomography/Computed Tomographyâ€“Based Assessments of Androgen Receptor Expression and Glycolytic Activity as a Prognostic Biomarker for Metastatic Castration-Resistant Prostate Cancer. JAMA Oncology, 2018, 4, 217.	7.1	93
14	Altered Biodistribution of Radiopharmaceuticals: Role of Radiochemical/Pharmaceutical Purity, Physiological, and Pharmacologic Factors. Seminars in Nuclear Medicine, 2010, 40, 220-241.	4.6	92
15	Comparison of ¹⁸F-FDG PET/CT for Systemic Staging of Newly Diagnosed Invasive Lobular Carcinoma Versus Invasive Ductal Carcinoma. Journal of Nuclear Medicine, 2015, 56, 1674-1680.	5.0	92
16	¹⁸F-FDG PET of Locally Invasive Breast Cancer and Association of Estrogen Receptor Status with Standardized Uptake Value: Microarray and Immunohistochemical Analysis. Journal of Nuclear Medicine, 2010, 51, 543-550.	5.0	86
17	A Prospective Pilot Study of ⁸⁹ Zr-J591/Prostate Specific Membrane Antigen Positron Emission Tomography in Men with Localized Prostate Cancer Undergoing Radical Prostatectomy. Journal of Urology, 2014, 191, 1439-1445.	0.4	73
18	miR-1207-3p regulates the androgen receptor in prostate cancer via FNDC1/fibronectin. Experimental Cell Research, 2016, 348, 190-200.	2.6	67

#	Article	IF	Citations
19	Pairwise comparison of 89Zr- and 124I-labeled cG250 based on positron emission tomography imaging and nonlinear immunokinetic modeling: in vivo carbonic anhydrase IX receptor binding and internalization in mouse xenografts of clear-cell renal cell carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 985-994.	6.4	65
20	Patterns of Lymph Node Failure after Dose-escalated Radiotherapy: Implications for Extended Pelvic Lymph Node Coverage. European Urology, 2017, 71, 37-43.	1.9	64
21	Utility of FDGâ€PET in clinical neuroendocrine prostate cancer. Prostate, 2014, 74, 1153-1159.	2.3	55
22	Galliumâ€68 DOTATATE PET in the Evaluation of Intracranial Meningiomas. Journal of Neuroimaging, 2019, 29, 650-656.	2.0	55
23	Metabolic tumor volume and total lesion glycolysis on FDG-PET/CT can predict overall survival after 90Y radioembolization of colorectal liver metastases: A comparison with SUVmax, SUVpeak, and RECIST 1.0. European Journal of Radiology, 2016, 85, 1224-1231.	2.6	47
24	Disparities in Castration-Resistant Prostate Cancer Trials. Journal of Clinical Oncology, 2015, 33, 1101-1103.	1.6	43
25	Radioembolization as a Salvage Therapy for Heavily Pretreated Patients With Colorectal Cancer Liver Metastases: Factors That AffectÂOutcomes. Clinical Colorectal Cancer, 2015, 14, 296-305.	2.3	40
26	Review of Salvage Therapy for Biochemically Recurrent Prostate Cancer: The Role of Imaging and Rationale for Systemic Salvage Targeted Anti-Prostate-Specific Membrane Antigen Radioimmunotherapy. Advances in Urology, 2012, 2012, 1-8.	1.3	36
27	Striatal dopamine type 2 receptor availability in anorexia nervosa. Psychiatry Research - Neuroimaging, 2015, 233, 380-387.	1.8	34
28	Immediate Postablation ¹⁸F-FDG Injection and Corresponding SUV Are Surrogate Biomarkers of Local Tumor Progression After Thermal Ablation of Colorectal Carcinoma Liver Metastases. Journal of Nuclear Medicine, 2018, 59, 1360-1365.	5.0	33
29	Early magnetic resonance imaging biomarkers to predict local control after high dose stereotactic body radiotherapy for patients with sarcoma spine metastases. Spine Journal, 2016, 16, 291-298.	1.3	32
30	Targeting of radiolabeled J591 antibody to PSMA-expressing tumors: optimization of imaging and therapy based on non-linear compartmental modeling. EJNMMI Research, 2016, 6, 7.	2.5	32
31	Presynaptic dopamine deficit in minimally conscious state patients following traumatic brain injury. Brain, 2019, 142, 1887-1893.	7.6	32
32	Stereotactic body radiotherapy for metastatic spinal sarcoma: a detailed patterns-of-failure study. Journal of Neurosurgery: Spine, 2016, 25, 52-58.	1.7	31
33	Phase I trial of docetaxel plus lutetium-177-labeled antiâ€“prostateâ€specific membrane antigen monoclonal antibody J591 (177Luâ€J591) for metastatic castrationâ€resistant prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 848.e9-848.e16.	1.6	29
34	Pilot Study of Hyperfractionated Dosing of Lutetium-177â€“Labeled Antiprostate-Specific Membrane Antigen Monoclonal Antibody J591 (177Lu-J591) for Metastatic Castration-Resistant Prostate Cancer. Oncologist, 2020, 25, 477-e895.	3.7	26
35	A simple strategy to reduce the salivary gland and kidney uptake of PSMA-targeting small molecule radiopharmaceuticals. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2642-2651.	6.4	26
36	Prostate-Specific Membrane Antigen Uptake and Survival in Metastatic Castration-Resistant Prostate Cancer. Frontiers in Oncology, 2021, 11, 630589.	2.8	26

#	Article	IF	Citations
37	PVT1 Exon 9: A Potential Biomarker of Aggressive Prostate Cancer?. International Journal of Environmental Research and Public Health, 2016, 13, 12.	2.6	24
38	Carotid Plaque Positron Emission Tomography Imaging and Cerebral Ischemic Disease. Stroke, 2019, 50, 2072-2079.	2.0	24
39	Phase I study of ²²⁵Ac-J591 for men with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2021, 39, 5015-5015.	1.6	24
40	Individual Patient Data Analysis of Randomized Clinical Trials: Impact of Black Race on Castration-resistant Prostate Cancer Outcomes. European Urology Focus, 2016, 2, 532-539.	3.1	23
41	Thyroid Cancer Bone Metastasis. Clinical Nuclear Medicine, 2019, 44, e465-e471.	1.3	22
42	[68Ga]-DOTATATE PET/MRI as an adjunct imaging modality for radiation treatment planning of meningiomas. Neuro-Oncology Advances, 2021, 3, vdab012.	0.7	20
43	Anatomic and functional imaging in the diagnosis of spine metastases and response assessment after spine radiosurgery. Neurosurgical Focus, 2017, 42, E5.	2.3	19
44	Dose-escalation results of a phase I study of 225Ac-J591 for progressive metastatic castration resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2020, 38, 114-114.	1.6	17
45	Automated Framework for Digital Radiation Dose Index Reporting From CT Dose Reports. American Journal of Roentgenology, 2011, 197, 1170-1174.	2.2	16
46	miR-1207-3p Is a Novel Prognostic Biomarker of Prostate Cancer. Translational Oncology, 2016, 9, 236-241.	3.7	16
47	The Influence of Diabetes Mellitus and Metformin on Distant Metastases in Oropharyngeal Cancer: A Multicenter Study. International Journal of Radiation Oncology Biology Physics, 2016, 94, 523-531.	0.8	16
48	Imaging expression of prostateâ€specific membrane antigen and response to PSMAâ€targeted Î²â€emitting radionuclide therapies in metastatic castrationâ€resistant prostate cancer. Prostate, 2021, 81, 279-285.	2.3	14
49	Molecular Imaging of Striatal Dopaminergic Neuronal Loss and the Neurovascular Unit in Parkinson Disease. Frontiers in Neuroscience, 2020, 14, 528809.	2.8	13
50	A Perspective of the Future of Nuclear Medicine Training and Certification. Seminars in Nuclear Medicine, 2016, 46, 88-96.	4.6	12
51	Pan-Cancer Analysis of Genomic Sequencing Among the Elderly. International Journal of Radiation Oncology Biology Physics, 2017, 98, 726-732.	0.8	11
52	Phase 1 study of radiosensitization using bortezomib in patients with relapsed non-Hodgkin lymphoma receiving radioimmunotherapy with131I-tositumomab. Leukemia and Lymphoma, 2015, 56, 342-346.	1.3	10
53	68Ga-PSMA-HBED-CC PET/MRI is superior to multiparametric magnetic resonance imaging in men with biochemical recurrent prostate cancer: A prospective single-institutional study. Translational Oncology, 2022, 15, 101242.	3.7	10
54	Evaluating diagnostic accuracy and determining optimal diagnostic thresholds of different approaches to [68Ga]-DOTATATE PET/MRI analysis in patients with meningioma. Scientific Reports, 2022, 12, .	3.3	10

#	Article	IF	Citations
55	Phase I dose-escalation study of PSMA-targeted alpha emitter 225Ac-J591 in men with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2020, 38, 5560-5560.	1.6	9
56	Review of commonly used prostate specific PET tracers used in prostate cancer imaging in current clinical practice. Clinical Imaging, 2021, 79, 278-288.	1.5	8
57	Pilot study of the diagnostic utility of 89 Zrâ€dfâ€IAB2M and 68 Gaâ€PSMAâ€11 PET imaging and multiparametric MRI in localized prostate cancer. Prostate, 2022, , .	2.3	8
58	Cholecystokinin-Assisted Hydrodissection of the Gallbladder Fossa during FDG PET/CT-guided Liver Ablation. CardioVascular and Interventional Radiology, 2013, 36, 1704-1706.	2.0	7
59	Repeatability of [68Ga]DKFZ11-PSMA PET Scans for Detecting Prostate-specific Membrane Antigen-positive Prostate Cancer. Molecular Imaging and Biology, 2017, 19, 944-951.	2.6	7
60	Theragnostic Target, Prostate-Specific Membrane Antigenâ€"Also Specific for Nonprostatic Malignancies. International Journal of Radiation Oncology Biology Physics, 2018, 101, 646-649.	0.8	6
61	Dynamic ⁶⁸Ga-DOTATATE PET/MRI in the Diagnosis and Management of Intracranial Meningiomas. Radiology Imaging Cancer, 2022, 4, e210067.	1.6	6
62	ACR Practice Parameter for the Performance of Therapy With Unsealed Radiopharmaceutical Sources. Clinical Nuclear Medicine, 2016, 41, 106-117.	1.3	4
63	[89Zr]Zr-huJ591 immuno-PET targeting PSMA in IDH mutant anaplastic oligodendroglioma. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 783-785.	6.4	4
64	PSMA-targeted dendrimers: a patent evaluation (WO2012078534). Expert Opinion on Therapeutic Patents, 2013, 23, 665-668.	5.0	3
65	Cancer Health Impact Program (CHIP): Identifying Social and Demographic Associations of mHealth Access and Cancer Screening Behaviors Among Brooklyn, New York, Residents. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 478-485.	2.5	3
66	Prostate-Specific Membrane Antigen Positron Emission Tomography and the New Algorithm for Patients With Prostate Cancer Prior to Prostatectomy. JAMA Oncology, 2021, 7, 1642.	7.1	3
67	A Phase II, Nonrandomized Open Trial Assessing Pain Efficacy with Radium-223 in Symptomatic Metastatic Castration-resistant Prostate Cancer. Clinical Genitourinary Cancer, 2021, 19, 447-456.	1.9	3
68	Tc-99m labeled small-molecule inhibitors of prostate-specific membrane antigen (PSMA): New molecular imaging probes to detect metastatic prostate adenocarcinoma (PC).. Journal of Clinical Oncology, 2012, 30, 173-173.	1.6	3
69	A Worrisome Interventricular Septum. Journal of the American College of Cardiology, 2011, 58, e43.	2.8	2
70	Roundtable on the Future of Nuclear Medicine Training. Journal of Nuclear Medicine, 2015, 56, 1966-1969.	5.0	2
71	FDG-Avid Intrathecal Inflammation Following Administration of Intrathecal Methotrexate. Clinical Nuclear Medicine, 2016, 41, 995-997.	1.3	2
72	A phase I/II dose-escalation study of fractionated and multiple dose 225Ac-J591 for progressive metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2021, 39, TPS188-TPS188.	1.6	2

#	Article	IF	Citations
73	Utility of [18F]-Fluoroestradiol (FES) PET/CT with dedicated brain acquisition in differentiating brain metastases from post treatment change in estrogen receptor-positive breast cancer. Neuro-Oncology Advances, 2021, 3, vdab178.	0.7	2
74	Phase I/II trial of pembrolizumab and AR signaling inhibitor +/- 225Ac-J591 for chemo-naive metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2022, 40, TPS216-TPS216.	1.6	2
75	952 ANTI-PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA)-BASED RADIOIMMUNOTHERAPY FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (CRPC): A DECADE OF EXPERIENCE WITH RADIOLABELED (RL)-J591. Journal of Urology, 2012, 187, .	0.4	1
76	Guest Editorial. Seminars in Nuclear Medicine, 2016, 46, 3-4.	4.6	1
77	Pilot study of anti-prostate-specific membrane antigen (PSMA) antibody J591 for men with metastatic castration-resistant prostate cancer (mCRPC) and unfavorable circulating tumor cell (CTC) count.. Journal of Clinical Oncology, 2021, 39, 120-120.	1.6	1
78	Baseline and post-treatment circulating tumor cell (CTC) counts with prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy (TRT) in men with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2021, 39, 158-158.	1.6	1
79	Phase 1 Study of Radiosensitization Using Bortezomib in Patients with Relapsed Non-Hodgkin's Lymphoma Receiving Radioimmunotherapy,. Blood, 2011, 118, 3712-3712.	1.4	1
80	Phase II trial of 177lutetium radiolabeled anti-PSMA antibody J591 (177Lu-J591) for metastatic castrate-resistant prostate cancer (metCRPC): Survival update and expansion cohort with biomarkers.. Journal of Clinical Oncology, 2013, 31, 121-121.	1.6	1
81	Phase 1 Study of Radiosensitization Using Bortezomib in Patients with Relapsed Non-Hodgkin's Lymphoma Receiving Radioimmunotherapy. Blood, 2012, 120, 1636-1636.	1.4	1
82	Phase I/II dose-escalation trial of fractionated dose 177Lu-J591 plus 177Lu-PSMA-617 for metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2019, 37, TPS339-TPS339.	1.6	1
83	Patient-reported outcomes (PRO) from a phase I/II dose-escalation study of fractionated dose 177Lu-PSMA-617 for progressive metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2020, 38, 45-45.	1.6	1
84	Assessment of patient-reported outcomes (PROs) and longer-term adverse events (AEs) in phase I study of ²²⁵Ac-J591-PSMA for metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2022, 40, 77-77.	1.6	1
85	Phase I/II study of ²²⁵Ac-J591 plus ¹⁷⁷Lu-PSMA-I&T for progressive metastatic castration-resistant prostate cancer.. Journal of Clinical Oncology, 2022, 40, TPS5100-TPS5100.	1.6	1
86	Prostate Specific Membrane Antigen-Based Therapeutics. , 2013, , 459-466.		0
87	NEIM-05. [GA68]DOTATATE PET/MRI-BASED RADIOSURGICAL RESPONSE ASESSMENT IN MENINGIOMA. Neuro-Oncology Advances, 2021, 3, iv7-iv7.	0.7	0
88	Prostate Specific Membrane Antigen-Based Diagnostics. , 2013, , 445-457.		0
89	Quantitative assessment of PSMA imaging before and after ¹⁷⁷Lu-PSMA-617 treatment in a Ph I/II trial.. Journal of Clinical Oncology, 2022, 40, 37-37.	1.6	0
90	Self-reported race and zip code by men with prostate cancer in New York City and association with access to PSMA PET scans.. Journal of Clinical Oncology, 2022, 40, e17007-e17007.	1.6	0